Drug
Cusatuzumab
Cusatuzumab: highest development phase Phase 1, developed by Argenx. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Argenx
Trials
| Drug | Phase | Indication |
|---|---|---|
| Cusatuzumab NCT04241549 | Phase 1 | Leukemia, Myeloid, Acute |
| Cusatuzumab NCT04150887 | Phase 1 | Leukemia, Myeloid, Acute |
Latest
No recent events.
Follow Cusatuzumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.